Skip to main content

Kymriah FDA Approval History

Last updated by Judith Stewart, BPharm on June 1, 2022.

FDA Approved: Yes (First approved August 30, 2017)
Brand name: Kymriah
Generic name: tisagenlecleucel
Dosage form: Suspension for Intravenous Infusion
Previous Name: CTL019
Company: Novartis Pharmaceuticals Corporation
Treatment for: Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Follicular Lymphoma

Kymriah (tisagenlecleucel) is a chimeric antigen receptor T cell (CAR-T) therapy for the treatment of B-cell acute lymphoblastic leukemia (ALL), large B-cell lymphoma, and follicular lymphoma (FL).

Development timeline for Kymriah

May 27, 2022Approval FDA Approves Novartis Kymriah CAR-T Cell Therapy for Adult Patients with Relapsed or Refractory Follicular Lymphoma
May  1, 2018Approval Kymriah (tisagenlecleucel) Receives Second FDA Approval to Treat Appropriate Patients with Large B-Cell Lymphoma
Dec 10, 2017Primary Analysis Results from Novartis Pivotal JULIET Trial Show Kymriah (tisagenlecleucel) Sustained Complete Responses at Six Months in Adults with r/r DLBCL, a Difficult-to-Treat Cancer
Aug 30, 2017Approval FDA Approves Kymriah (tisagenlecleucel) CAR-T Gene Therapy for Acute Lymphoblastic Leukemia
Jul 12, 2017Novartis CAR-T Cell Therapy CTL019 Unanimously (10-0) Recommended for Approval by FDA Advisory Committee to Treat Pediatric, Young Adult r/r B-Cell ALL
Apr 18, 2017Novartis CAR-T Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation for Treatment of Adult Patients with r/r DLBCL
Mar 29, 2017Novartis Announces First CAR-T Cell Therapy BLA for Pediatric and Young Adult Patients with r/r B-Cell ALL Granted FDA Priority Review

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.